Sources revealed, data from the global trials would be submitted to the Indian regulator by the end of December
After Pfizer and Moderna, the much anticipated AstraZeneca-Oxford vaccine candidate has shown positive results in an interim analysis of clinical trials in the UK and Brazil, with a vaccine efficacy of up to 90 per cent in different dosing regimens.
Sources revealed, data from the global trials would be submitted to the Indian regulator by the end of December, and Serum Institute of India (SII), AstraZeneca’s manufacturing partner here, would submit the interim data from the Indian arm by then.
Tune in for more
Track Title by Scott Buckley – www.scottbuckley.com.au
 "Coronavirus vaccine: Things to know about process, timeline & effectiveness")
